

1/1 - (C) WPI / DERWENT  
 AN - 83-767184 25!  
 AP - JP820015574 820204  
 PR - JP820015574 820204  
 TI - Anticancer drug - comprising ribosome modified with  
 mono-clonal antibody  
 IW - ANTICANCER DRUG COMPRISE RIBOSOME MODIFIED MONO CLONE  
 ANTIBODY  
 PA - (HASH-I) HASHIMOTO Y  
 PN - JP58134032 A 830810 DW8338 003pp  
 - JP3055450B B 910823 DW9138 000pp  
 ORD - 1983-08-10  
 IC - A61K9/10 ; A61K31/71 ; A61K37/02 ; A61K39/44  
 FS - CPI  
 DC - B04  
 AB - J58134032 A ribosome modified with a monoclonal  
 antibody forms an anticancer material in particle  
 and/or membrane form. The ribosome exerts specifically  
 for cancer tissue and the anticancer material is  
 transferred into cancer cells. Therefore, the  
 anticancer drug containing the ribosome has little in  
 the way of side effects.  
 - The anticancer material is mixed into a soln. of the  
 constituent lipid of the ribosome and a monolayer  
 ribosome is formed by ultrasonic treatment etc. in a  
 conventional manner. Thereby, fat-soluble anticancer  
 material is uniformly dispersed into a membrane and  
 water-soluble anticancer material is enclosed in lipid  
 vesicle, and therefore the ribosome is present in the  
 form of microcapsule. To introduce the monoclonal  
 antibody into the membrane, an antibody fragment  
 carrying SH-gps. is used. For IgM, IgM antibody is  
 treated with e.g. cysteine to reduce only J-chain and  
 IgM subunit (IgMs) having two mercapto gps. is prepd.  
 Ribosome having many maleimide gps. originating from  
 m-maleimidebenzoyl -N-(dipalmitoylphosphatidyl)  
 ethanolamine on its membrane is used. IgMs is added to  
 the soln. of the ribosome in PBS and incubated at 37  
 deg.C for about 1 hr. to cause SH-addn. reaction.